CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 180 enrolled
Drug / intervention
CPP-ACP +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03865680
NCT03865680Phase 2Completed
CompareCT.gov

Effect of Casein Phosphopeptide Amorphous Calcium Phosphate Fluoride Varnish on Remineralization of White Spot Lesion in Primary Teeth (Randomized Clinical Trial)

Nourhan M.Aly·interventional·Posted Mar 7, 2019·Updated Apr 22, 2020

In Brief

A Phase 2 clinical trial evaluating CPP-ACP and Duraphat for White Spot Lesion. Completed, enrolled 180 participants across 1 site.

Detailed Summary

The aim of this study is to evaluate the effectiveness of Casein phosphopeptide-amorphous calcium phosphate fluoride varnish (CPP-ACP FV) in comparison to fluoride varnish (FV) as a remineralizing agent for white spot lesions in primary teeth (WSLs).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWhite Spot Lesion
CountriesEgypt
CollaboratorsAlexandria University

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMar 7, 2019
Enrollment StartApr 28, 2019
Primary CompletionMar 25, 2020
Study CompletionApr 10, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.3 years ago

Interventions

CPP-ACPdrug

The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.

Duraphatdrug

The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.